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Abstract
We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis pa-
tients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such
patients. For comparison, the same parameters were also investigated in 10 cancer patients not un-
dergoing dialysis. Items investigated included (1) plasma concentrations of SN-38, SN-38G and
CPT-11 at 0, 1, 12, 24, 36, 48 and 72h after administration, together with a comparison of mean
AUC values for 3 dose levels of CPT-11 (50, 60 and 70mg/m2) in dialysis patients and controls;and
(2) occurrence of adverse events. Several findings emerged from this study:(1) No significant dif-
ference was observed in the AUC for SN-38 or CPT-11 between the dialysis and control groups;(2)
The AUC for SN-38G at each dose was significantly higher in dialysis patients;and (3) Grade 1-4
leucopenia was observed in 11 of the dialysis patients. One patient developed grade 4 leucopenia
and died due to sepsis. Anorexia, diarrhea, nausea, alopecia and interstitial pneumonia occurred
in 6 dialysis patients. We found changes in drug dispositions of CPT-11, SN-38 and SN-38G in
dialysis patients, suggesting that hepatic excretion, especially that of SN-38G, was increased. No
significant difference in occurrence of adverse events was observed between the 2 groups. This
indicates that CPT-11 can be administered safely in patients on dialysis.
KEYWORDS: irinotecan hydrochloride (CPT-11), chronic kidney disease (CKD), end-stage re-
nal disease (ESRD), dialysis, colorectal cancer
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We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with 
gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients.  For 
comparison,  the same parameters were also investigated in 10 cancer patients not undergoing dialysis.  
Items investigated included (1) plasma concentrations of SN-38,  SN-38G and CPT-11 at 0,  1,  12,  24,  
36,  48 and 72h after administration,  together with a comparison of mean AUC values for 3 dose lev-
els of CPT-11 (50,  60 and 70mg/m2) in dialysis patients and controls; and (2) occurrence of adverse 
events.  Several ﬁndings emerged from this study: (1) No signiﬁcant diﬀerence was observed in the 
AUC for SN-38 or CPT-11 between the dialysis and control groups; (2) The AUC for SN-38G at each 
dose was signiﬁcantly higher in dialysis patients; and (3) Grade 1-4 leucopenia was observed in 11 of 
the dialysis patients.  One patient developed grade 4 leucopenia and died due to sepsis.  Anorexia,  diar-
rhea,  nausea,  alopecia and interstitial pneumonia occurred in 6 dialysis patients.  We found changes in 
drug dispositions of CPT-11,  SN-38 and SN-38G in dialysis patients,  suggesting that hepatic excretion,  
especially that of SN-38G,  was increased.  No signiﬁcant diﬀerence in occurrence of adverse events was 
observed between the 2 groups.  This indicates that CPT-11 can be administered safely in patients on 
dialysis.
Key words: irinotecan hydrochloride (CPT-11),  chronic kidney disease (CKD),  end-stage renal disease 
(ESRD),  dialysis,  colorectal cancer
s the most eﬀective curative treatment currently 
available,  surgery is the option of choice for 
gastrointestinal cancers,  while chemotherapy is the 
main option for both limited-stage and inoperative 
metastatic cancers.  In patients on dialysis,  the inci-
dence and mortality of cancer have been shown to be 
higher than the predicted rates in the general popula-
tion due to variable immunodeﬁciency [1-3].  One of 
the routes that anticancer drugs take as they are dis-
charged from the body is through the kidneys,  which 
are easily impaired.  Therefore,  chemotherapy is not 
performed aggressively in patients on dialysis,  as its 
safety has yet to be established in patients with 
chronic renal failure.  Irinotecan hydrochloride (CPT-
A
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11) was ﬁrst approved in the United States in 1996,  
and was the standard of care for second-line therapy 
in 5-FU-refractory colorectal cancer (CRC) at the 
inception of the current trial [4,  5].  The incorpora-
tion of CPT-11 has proved a promising strategy in 
improving survival in patients with CRC [4-6].  
However,  no consensus has been established on the 
safety of CPT-11 in patients on dialysis.
　 In this study,  we investigated changes in drug 
disposition and toxicities with CPT-11 in patients with 
gastrointestinal cancers who were on dialysis to clar-
ify whether CPT-11 could be administered safely in 
such patients.  This study was approved by the institu-
tional review board of this facility.  Written informed 
consent was obtained from all patients prior to enroll-
ment.
Patients and Methods
　 A total of 15 patients with gastrointestinal cancers 
who were on dialysis were enrolled in this study 
between March,  2005 and April,  2008 at the Hachioji 
Medical Center of Tokyo Medical University.  These 
15 patients consisted of 10 men and 5 women,  with a 
median age of 71.1 years (range 63-84 years) and 
median performance status of 1 (range 0-2).  The 
results of the liver function tests for the 15 patients 
were as follows: median AST,  20.7IU/L (range,  6-41 
IU/L); median ALT,  13.5IU/L (range,  3-25IU/L);  
and median total bilirubin,  0.42mg/dL (range,  0.2-
0.8mg/dL).  Histologically,  11 of the 15 patients were 
diagnosed with colorectal cancer and 4 with gastric 
cancer.  The patients had been on hemodialysis for 
1-168 months,  and none had received pre-treatment.  
Thirteen patients underwent surgical therapy at our 
department (Table 1).  Ten non-dialysis patients with 
cancers (4 with colorectal,  2 with stomach,  2 with 
biliary tract and 2 with lung cancer) donated sera for 
comparison as controls.  They included 7 men and 3 
women; median age,  61.4 years (range,  35-79 years);  
median eGFR,  76.3mL/min/1.73m2 (range,  61.5-
91.7mL/min/1.73m2);  and median serum creatinine,  
0.6mg/dL (range,  0.5-1.0mg/dL).
　 CPT-11 was provided by Yakult Honsha Co.  Ltd.  
(Tokyo,  Japan) as a solution ready for use in 2- or 
5-ml vials containing 40 and 100mg of the drug,  
respectively.  CPT-11 was diluted with 500mL 
sodium chloride and administered by intravenous infu-
sion over 90min within 2h of completion of hemodialy-
sis.  Three dose levels of CPT-11 were studied: 50,  
60 and 70mg/m2.  Dosage was increased in 10-mg/m2 
increments from 50 to 70mg/m2.
　 Analysis of CPT-11 in plasma and data 
evaluation. To assess changes in drug disposition 
of CPT-11 (the unchanged compound),  its active 
metabolite,  7-ethyl-10-hydroxycampothecin (SN-38),  
and SN-38G (the glucuronide),  serial blood samples 
were collected into 6.0-ml tubes at the following 
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Table 1　 Disease characteristics of enrolled patients
No. Sex Age PS HDduration (m) Origin Procedure Stage
1 M 69 2 50 A/C － Ⅳ(H3)
2 F 66 1 5 Rectum － －
3 M 75 2 110 Rectum Hartmann Ⅲ
4 F 63 2 48 S/C Hartmann Ⅲ
5 M 68 0 1 Rectum Hartmann Ⅱ
6 F 81 1 1 S/C HAR Ⅱ
7 M 75 0 66 T/C Rt.-hemi Ⅲ
8 M 67 1 8 A/C Rt.-hemi Ⅰ
9 M 67 0 2 S/C HAR Ⅱ
10 F 68 1 168 A/C Rt.-hemi Ⅲb
11 F 66 1 144 S/C HAR Ⅳ(H3)
12 M 67 1 6 Stomach Total Ⅱ
13 M 72 1 3 Stomach Distal Ⅱ
14 M 84 1 1 Stomach Distal ⅠA
15 M 78 1 76 Stomach Total ⅠB
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times: t＝0 (immediately after completion of CPT-11 
infusion) and at 1,  12,  24,  36,  48 and 72h after 
administration.  Blood samples were centrifuged at 
3,500g for 5min,  and the plasma was transferred into 
polypropylene tubes,  followed by addition of 0.146 
MH3PO4.  The standard samples were stored at 
－20℃.  Plasma samples were analyzed for SN-38,  
SN-38G and CPT-11 using a validated high-perfor-
mance liquid chromatography (HPLC) method and the 
PROSPECT fully automated on-line solid-phase 
extraction system [7].  The areas under the plasma 
concentration vs.  time curves (AUCs) for SN-38,  
SN-38G and CPT-11 were calculated for each dose.  
The AUC value was determined using the trapezoidal 
method with MOMENT (EXCEL) [8].
　 Items investigated.
　 1) Mean AUC values for each dose were compared 
between dialysis patients and controls.
　 2) Occurrence of adverse events.
Toxicity was evaluated in all patients receiving 1-3 
cycles of CPT-11.  Toxicities (hematological and non-
hematological) were graded according to the National 
Cancer Institute Common Toxicity Criteria (NCI-
CTC),  revised version 2.0.  Hematological toxicity 
was assessed based on blood cell count and blood 
chemistry data obtained twice weekly,  with worst 
toxicity being reported.  Hemoglobin,  blood urea 
nitrogen (BUN),  creatinine and electrolyte levels 
were excluded from the assessment as all 15 patients 
on dialysis had developed anemia and renal dysfunc-
tion.  All patients in both groups were given G-CSF 
when they developed grade 3 febrile leucopenia (white 
blood cell count＜1,500cells/mm3) or grade 4 non-
febrile leucopenia (white blood cell count＜
1,000cells/mm3).
　 Statistical analysis. Diﬀerences in AUCs 
between dialysis patients and controls were compared 
using an unpaired t-test.  All p values reported are 
two-tailed,  and all tests were performed at a 0.05 
signiﬁcance level.  Statistical analysis of the data was 
conducted using the GraphPad software (San Diego,  
CA,  USA).
Results
　 AUC values. Figs.  1,  2 and 3 show the blood 
concentration curves after CPT-11 administration for 
SN-38,  SN-38G and CPT-11 in the dialysis patients 
and the controls.  There appeared to be no increase in 
the AUC for SN-38,  SN-38G or CPT-11 among the 
successive dose levels (50,  60 and 70mg/m2).  No 
signiﬁcant diﬀerence between the 2 groups was 
observed in mean AUC values and standard errors for 
SN-38 or CPT-11 obtained at each dose (50,  60 and 
70mg/m2; Table 2).  On the other hand,  the mean and 
standard error of the AUC values for SN-38G at each 
dose (50,  60 and 70mg/m2) were signiﬁcantly higher 
in the dialysis patients than in the controls (Table 2).
　 Intensity of adverse events.
　 1. Hematologic Toxicities. The main adverse 
reaction was myelotoxicity,  with leucopenia occurring 
75.0ｵ (24/32cycles) in 11 (73.3ｵ) patients: 4 
patients with grade 1,  3 patients with grade 2,  3 
patients with grade 3,  and 1 patient with grade 4 after 
administration of 50-70mg/m2 CPT-11.  Four patients 
(26.7ｵ) showed grade 3 or 4 leucopenia.  Although 
one patient with grade 4 leucopenia after administra-
tion of 70mg/m2 was treated with G-CSF,  he died due 
to sepsis and pneumonia (Table 3).  No thrombocy-
topenia was observed,  and no patient required a blood 
transfusion in any cycle.
　 2. Non-hematologic Toxicities. Anorexia,  diar-
rhea,  nausea,  alopecia and interstitial pneumonia 
occurred in 6 patients (Table 4).
Discussion
　 Camptothecin (CPT),  a plant alkaloid extract from 
the Chinese tree Camptotheca acuminate,  has strong 
antitumor activity due to its inhibition of the nuclear 
enzyme DNA topoisomerase-1 (Topo-1) [9-11].  
Irinotecan hydrochloride,  a water-soluble derivative 
of camptothecin developed to improve its antitumor 
activity and decrease its toxicity in mice and rats [12,  
13],  has been shown to be highly eﬀective in the 
treatment of metastatic colorectal cancer [4-6]; and 
CPT-11 with 5-ﬂuorouracil (5-FU) and leucovorin 
(LV) has been shown to be eﬀective for metastatic 
colorectal cancer in large randomized phase three 
trials [14,  15].  These studies [4-6,  14,  15] formed 
the basis for the selection of CPT-11 for investigation 
in the present study.
　 Only a small fraction of the administered CPT-11 
is metabolized by carboxylesterase enzymes [16,  17] 
to SN-38,  which is a signiﬁcantly more potent inhibi-
tor of tumor activity [18].  In addition,  SN-38 is 
21Irinotecan in Cancer Patients on DialysisFebruary 2010
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conjugated by the polymorphic enzyme uridine diphos-
phate glucuronosyltransferase 1A1 (UGT1A1) to 
SN-38 glucuronide (SN-38G) [16,  19-21],  which is 
excreted in the bile,  urine and feces [21].  Slatter et 
al.  noted that CPT-11 was the major excretory prod-
uct in bile,  urine and feces,  and that fecal excretion 
accounted for 63.7±6.8ｵ of the dose,  whereas urine 
excretion accounted for 32.2±6.9ｵ after intravenous 
infusion of CPT-11 in 7 patients with solid tumors 
[22].  SN-38 was shown to be a signiﬁcant metabolite 
in feces (8.24±2.51ｵ) and urine (0.43±0.12ｵ) 
[22].  These data may explain why no signiﬁcant dif-
ference was observed in the mean AUC values for 
CPT-11 and SN-38 between the dialysis patients and 
the controls in this study.  On the other hand,  SN-38G 
was also shown to be a signiﬁcant metabolite in urine 
(3.02±0.77ｵ) and feces (0.27±0.17ｵ) [22].  This 
may explain why the mean AUC values for SN-38G 
were signiﬁcantly higher in the dialysis patients than 
in the controls here.  In other words,  the absence of 
renal clearance of SN-38G in the dialysis patients led 
to a signiﬁcant increase in their AUC value for 
SN-38G.
　 Furthermore,  these results suggest that SN-38G 
was exclusively excreted in the feces in dialysis 
patients,  and that enterohepatic circulation of SN-38 
was slight or absent.  If enterohepatic circulation of 
SN-38 was present,  the mean plasma AUC value for 
SN-38 would have been higher in the dialysis patients 
than in the controls.  However,  no signiﬁcant diﬀer-
ence was observed in the mean AUC values for SN-38 
between the 2 groups.  Asai et al.  reported the accu-
rate estimation of the AUC of carboplatin following 
irinotecan using a limited sampling model [23].  They 
22 Acta Med.  Okayama　Vol.  64,  No.  1Ashizawa et al.
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Fig. 1　 SN-38 blood concentration curves after administration of CPT-11 at 50mg/m2 (A),  60mg/m2 (B) and 70mg/m2 (C) in dialysis 
patients and controls.
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noted that the dispersion of the AUC value was 
greater in the limited sampling model and that drug-
drug interactions might alter the pharmacokinetics of 
carboplatin [23].  However,  as no 5-FU or LV was 
administered along with CPT-11 to the patients in our 
study,  the inﬂuence of such interactions on the phar-
macokinetics of CPT-11 was not investigated.
　 Although CPT-11 shows marked anti-cancer activ-
ity,  this drug also shows certain side eﬀects.  These 
include a decrease in blood cells,  especially neutro-
phils,  alopecia,  nausea and gastrointestinal toxicities 
such as diarrhea [24,  25].  Rothenberg noted that 
diarrhea and myelosuppression remained the most 
clinically signiﬁcant and common toxicities of irinote-
can (CPT-11) [26].  In the present study,  no signiﬁ-
cant diﬀerence was observed in the occurrence of 
leucopenia between our results (73.3ｵ) and those of 
previous clinical reports (75.8～91ｵ) [4,  6,  25].  
Eleven patients developed grade 1-4 leucopenia and 4 
patients (26.7ｵ) developed grade 3/4 leucopenia.  In 
10 out of these 11 patients,  leucopenia was resolved 
by conservative treatment including G-CSF,  while the 
remaining patient with grade 4 leucopenia died due to 
sepsis.  Although this latter patient received G-CSF 
when he developed grade 3 leucopenia,  the white 
blood cell count showed no improvement,  and the 
leucopenia progressed to grade 4.  In dialysis patients,  
it is necessary to investigate the timing of G-CSF 
administrations,  as the reactivity of G-CSF diﬀers in 
such patients.  Kurita et al.  noted that one pharma-
cokinetic parameter (Cmax) of CPT-11 was closely 
related to the incidence and severity of myelosuppres-
sion [27].  However,  the pharmacodynamic relation-
ship between the AUCs for SN-38,  SN-38G (glucu-
ronate) and CPT-11 showed no correlation with the 
severity of leucopenia in this study.
23Irinotecan in Cancer Patients on DialysisFebruary 2010
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Fig. 2　 SN-38G blood concentration curve after administration of CPT-11 at 50mg/m2 (A),  60mg/m2 (B) and 70mg/m2 (C) in dialysis 
patients and controls.
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　 CPT-11 and its active metabolite SN-38 induce 
non-speciﬁc gastrointestinal symptoms,  especially 
diarrhea,  which has been recognized as a dose-limit-
ing factor [28].  It has been suggested that there are 
two diﬀerent mechanisms by which CPT-11 induces 
acute (functional) and delayed diarrhea [29,  30].  It is 
assumed that acute diarrhea occurs not only due to 
inhibition of cholinesterase activity,  resulting in cho-
linergic syndrome [29,  31],  but also to activation of 
the 5-HT3 receptor [32].  In other words,  the cholin-
ergic activity of CPT-11 stimulates intestinal contrac-
tility,  disturbing normal intestinal mucosal absorptive 
and secretory functions [29,  32,  33].  On the other 
24 Acta Med.  Okayama　Vol.  64,  No.  1Ashizawa et al.
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Fig. 3　 CPT-11 blood concentration curve after administration of CPT-11 at 50mg/m2 (A),  60mg/m2 (B) and 70mg/m2 (C) in dialysis 
patients and controls.
Table 2　 Comparison of mean AUC value between dialysis 
patients and controls
Variable Dose(mg/m2)
Patients
(µg・h/mL)
Controls
(µg・h/mL) P-value
50 0.22±0.07 0.26±0.11 N.S.
SN-38 60 0.19±0.03 0.18±0.02 N.S.
70 0.17±0.03 0.22±0.08 N.S.
50 3.64±1.21 0.74±0.53 ＜0.01
SN-38G 60 3.42±0.98 0.64±0.29 ＜0.01
70 2.73±0.88 0.62±0.25 ＜0.01
50 3.55±1.00 3.47±1.21 N.S.
CPT-11 60 3.74±1.28 3.28±1.33 N.S.
70 2.94±1.11 3.86±2.00 N.S.
Table 3　 Incidence of leucopenia (per cycle) possibly or probably 
related to CPT-11 administration
CPT-11
(mg/m2)
Grade 1
No. (%)
Grade 2
No. (%)
Grade 3
No. (%)
Grade 4
No. (%)
50 6 (60) 1 (10) 2 (20) 0
60 3 (25) 3 (25) 2 (16.7) 1 (8.3)
70 1 (10) 3 (30) 2 (20) 0
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hand,  delayed diarrhea arises as a consequence of 
direct enteric injury by SN-38 and/or CPT-11 [30,  
34].
　 Previous clinical reports have reported incidence 
rates of diarrhea due to CPT-11 of 62.9～87ｵ [4,  
6,  25].  However,  only one patient developed acute 
diarrhea after administration of 70mg/kg CPT-11 in 
our study,  and his diarrhea was resolved without 
loperamide.  Generally speaking,  constipation occurs 
frequently in dialysis patients [35,  36],  due to a 
number of possible causes,  including restricted ﬂuid 
intake,  insuﬃcient dietary ﬁber,  disturbance of intes-
tinal mucosal absorption and bowel movement,  the side 
eﬀects of drugs,  and enforced physical inactivity.  
Among these,  insuﬃcient bowel movement due to dis-
turbance of autonomic nerve function has been sug-
gested to inhibit the mechanism that can lead to the 
onset of acute diarrhea with CPT-11.  As a result,  it 
is believed that diarrhea is unlikely to occur following 
administration of CPT-11 in dialysis patients.  The 
patient in our study who did develop diarrhea had been 
on dialysis for only 2 months,  and had had no episodes 
of constipation before administration of CPT-11.  
Hammer et al.  noted that the duration of dialysis 
showed no signiﬁcant inﬂuence on the prevalence of 
gastrointestinal symptoms,  although a trend was found 
towards a higher prevalence in patients who were on 
dialysis for more than 8 months [37].
　 In conclusion,  we found changes in drug disposi-
tion of CPT-11,  SN-38 and SN-38G in patients on 
dialysis,  suggesting that hepatic excretion was 
increased,  especially that of SN-38G.  In dialysis 
patients,  there is the concern that anuresis may cause 
an increase in side eﬀects.  However,  no increase in 
side eﬀects was observed with an increase in SN-38G 
in this study,  a ﬁnding which is of clinical importance.  
Moreover,  no diﬀerence was observed in the incidence 
of side eﬀects,  especially leucopenia,  between dialysis 
patients and non-dialysis patients,  which suggests lit-
tle or no enterohepatic circulation.  In 10 out of 11 
patients,  leucopenia was resolved by conservative 
treatment.  This indicates that CPT-11 can be admin-
istered safely in patients on dialysis.
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